EYPT
EyePoint Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow -8.9% ·
net new positions -7.1%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | +2 | 47.58M | $680.27M | +5 | −4 |
| Q1 2026 | 79 | +9 | 48.20M | $619.80M | +12 | −3 |
| Q4 2025 | 69 | +1 | 44.57M | $814.29M | +2 | −1 |
| Q3 2025 | 14 | -1 | 22.98M | $327.28M | n/a | −1 |
| Q2 2025 | 12 | 0 | 22.66M | $213.25M | n/a | n/a |
| Q1 2025 | 9 | -1 | 13.73M | $74.43M | n/a | −1 |
| Q4 2024 | 10 | 0 | 15.37M | $114.47M | +1 | −1 |
| Q3 2024 | 9 | -2 | 10.25M | $81.94M | n/a | −2 |
| Q2 2024 | 11 | n/a | 10.63M | $92.49M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 5.56M | -18.2% | $79.17M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 4.96M | -7.4% | $70.69M | 0.0% | ▼ Trim | 2 | SEC ↗ ×10 |
| 3 | The Vanguard Group ✦ (passive) | 3.79M | -0.2% | $54.03M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | Citadel Advisors ✦ | 2.14M | -8.9% | $30.41M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.52M | -4.2% | $21.71M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | Goldman Sachs Group ✦ | 1.51M | n/a | $21.57M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 1.47M | -2.8% | $20.98M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 978.13K | n/a | $13.93M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 9 | Millennium Management ✦ | 483.05K | +1166.2% | $6.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 215.45K | -18.7% | $3.07M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 11 | Two Sigma Investments ✦ | 179.44K | -52.4% | $2.56M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 81.91K | -2.1% | $1.17M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | JPMorgan Chase ✦ | 60.52K | n/a | $861,862 | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 14 | Fidelity (FMR) ✦ | 17.87K | -96.0% | $254,502 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $348,170 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 40.00K shares, $515 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 10.60K sh @ 4.93 · $52,258
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology